Retatrutide
Retatrutide (LY3437943)
The strongest fat-loss peptide on the bench — a triple agonist, the one the community calls the “king.” It hits three metabolic switches where the first-generation GLP-1 drugs hit one, which is exactly why it works so hard and why dosing it wrong makes people miserable.
What it is
People run it for one thing: fat loss — faster, and more of it, than anything else in the class. The standout reported effects are heavy appetite suppression and a sharp drop in “food noise,” plus visceral- and liver-fat reduction. It's the rare peptide here with real Phase-2 trial data behind the exact use people run it for.
Its whole identity is the three-receptor ladder the community recites constantly: semaglutide hits one receptor, tirzepatide two, retatrutide three — the extra one being the glucagon receptor. That third switch is what makes it the most powerful of the group, and also what gives it its signature: it raises metabolic rate hard enough that people describe it less like a standard GLP-1 and more like “biological overdrive.” The loudest community theme isn't hype, though — it's that most people who feel terrible on it dosed it wrong, not that the drug failed.
Mechanism
A triple agonist: it activates the GLP-1 and GIP receptors (like tirzepatide) plus the glucagon receptor — the third, and the differentiator. GLP-1 and GIP drive appetite suppression and insulin/glucose handling; glucagon-receptor activation raises energy expenditure and pushes fat, including visceral and liver fat, to be burned. That added glucagon load is the reason it's both more powerful and harder on the body than the one- and two-receptor drugs.
Step 1 · the class
Most fat-loss drugs flip one switch.
The first-generation GLP-1 drugs work a single receptor. Useful — but that is one lever on a system that has several.
Step 2 · the ladder
One receptor, then two.
The next generation added a second receptor, GIP, alongside GLP-1 — and worked harder for it. The pattern is simple: more switches, more effect.
Step 3 · the third switch
Retatrutide adds a third — glucagon.
It keeps GLP-1 and GIP and adds the glucagon receptor. Three switches where the others have one or two — the reason the community calls it the strongest of the class.
Step 4 · appetite goes quiet
GLP-1 and GIP cut the hunger signal.
The first two receptors do what the class is known for: appetite drops and the constant food noise goes quiet.
Step 5 · the furnace
The glucagon switch turns up the burn.
The third receptor is the differentiator — it raises how much energy the body spends. People describe it less like an appetite drug and more like metabolic overdrive.
Step 6 · fat burns
Including the fat that matters most.
That raised expenditure pulls fat down — notably visceral and liver fat, not just the number on the scale.
Step 7 · the cost
The switch that burns also strains.
Glucagon load raises resting heart rate — users cite roughly +10 bpm — and drives the nausea. This is why the advice is start low, titrate slow: most of the misery traces to dosing too high, too fast.
The result
The strongest lever — handled carefully.
Three receptors make it the most powerful in the class, with real trial data behind the fat-loss use. The power and the cost come from the same third switch.
Phase-2 RCTs back the fat-loss use — but it is still investigational, not approved. The side effects scale with the glucagon load, which is why the advice is start low and titrate slow.
Standard dose
| Starting dose | 0.5–1 mg / week — clinicians warn 2 mg is too aggressive on day one (proposed — pending dosing review)community |
|---|---|
| Titration | Step up every ~4 weeks: 0.5 → 1 → 2 → 4 mgcommunity |
| Effective range | Most settle at 2–4 mg / week; 12 mg is the trial ceiling, not a targetcommunity |
| Frequency / route | Once weekly, SubQ — splitting into multiple weekly shots is flagged for pancreatitis riskcommunity |
Reconstitution calculator
U-100 · 100u = 1 mL= 200 units
Set the vial size and water to match your product — amounts vary by supplier. This is unit-conversion math, not medical advice or a dosing recommendation.
Pushing higher— going beyond the standard dosecommunity
Side effects & cautions
Nausea is the most common, as with the whole GLP-1 class — but retatrutide has a signature the others don't: a noticeably elevated resting heart rate (users cite roughly +10 bpm), tied to the glucagon-receptor activation. Beyond that: fatigue, constipation or diarrhea, and sleep disruption — one widely-shared account describes waking at 3 a.m. with a racing heart and sweats. There's a smaller but real skin/itching signal. The biggest worry people raise isn't a side effect but muscle loss from rapid weight loss, which is why protein and resistance training dominate the conversation. Start low and titrate slowly — most of the misery here traces back to dosing too high, too fast.
Stacking
In practice it's run standalone for fat loss — there's no community peptide-stacking protocol for it. When people say “stack” with retatrutide they almost always mean the support around it, not other peptides: high protein intake and resistance training to protect muscle during fast weight loss, plus electrolytes and B12/micronutrients. The work is in the diet and training alongside it, not in pairing it with another compound.
Evidence & sources
The strongest evidence base on this site — and for the exact use people run it for. Published Phase-2 RCTs show up to ~24% body-weight loss at 48 weeks, with a large Phase-3 program (TRIUMPH) underway. The one caveat: it's still investigational, not FDA-approved, so the final safety/efficacy picture is pending.
- Jastreboff AM et al. (2023)Human RCTTriple-hormone-receptor agonist retatrutide for obesity (Phase 2)NEJM — ~24% body-weight loss at 48 wkPMID 37366315 ↗
- Rosenstock J et al. (2023)Human RCTRetatrutide in type 2 diabetes (Phase 2)Lancet — randomized controlled trialDOI 10.1016/S0140-6736(23)01053-X ↗
- Sanyal AJ et al. (2024)Human RCTRetatrutide for metabolic dysfunction-associated steatotic liver diseaseNature Medicine — liver-fat reductionDOI 10.1038/s41591-024-03018-2 ↗
- ClinicalTrials.gov (2023)Trial registryTRIUMPH — retatrutide Phase 3 obesity programClinicalTrials.gov — ongoingNCT05929066 ↗
- medRxiv preprint (2026)Human studyReddit retatrutide side-effect analysis (13,589 users; 57.6% reported ≥1 side effect)medRxiv — self-reported community dataDOI 10.64898/2026.05.28.26352819 ↗